Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Laurence Collette

Showing results (31-40 of 155) with videos related to

Pageof 16
Sort By:
BMC Medical Research Methodology|October 5, 2022
The case against censoring of progression-free survival in cancer clinical trials - A pandemic shutdown as an illustrationCorinne Jamoul, Laurence Collette, Elisabeth Coart, et al.
JAMA Network Open|May 17, 2021
Association of Increased Prostate-Specific Antigen Levels After Treatment and Mortality in Men With Locally Advanced vs Localized Prostate Cancer: A Secondary Analysis of 2 Randomized Clinical TrialsMartin T King, Ming-Hui Chen, Laurence Collette, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|August 9, 2011
Nomogram to predict ipsilateral breast relapse based on pathology review from the EORTC 22881-10882 boost versus no boost trialErik van Werkhoven, Guus Hart, Harm van Tinteren, et al.
The Lancet. Oncology|February 5, 2019
Towards an evidence-informed value scale for surgical and radiation oncology: a multi-stakeholder perspectiveYolande Lievens, Riccardo Audisio, Ian Banks, et al.
The Lancet. Oncology|April 4, 2019
ESMO-MCBS: setting the record straight - Authors' replyYolande Lievens, Riccardo Audisio, Ian Banks, et al.
Biometrical Journal. Biometrische Zeitschrift|September 17, 2020
A new measure of treatment effect in clinical trials involving competing risks based on generalized pairwise comparisonsEva Cantagallo, Mickaël De Backer, Michal Kicinski, et al.
Biometrical Journal. Biometrische Zeitschrift|February 22, 2021
Correcting the bias of the net benefit estimator due to right-censored observationsJulien Péron, Maryam Idlhaj, Delphine Maucort-Boulch, et al.
Acta Oncologica (Stockholm, Sweden)|June 24, 2008
Results of the phase II EORTC 22971 trial evaluating combined accelerated external radiation and chemotherapy with 5FU and cisplatin in patients with muscle invasive transitional cell carcinoma of the bladderPhilip M Poortmans, Pierre Richaud, Laurence Collette, et al.
Japanese Journal of Clinical Oncology|February 8, 2017
Collaboration between EORTC and JCOG-how to accelerate global clinical research partnershipKozo Kataoka, Kenichi Nakamura, Carmela Caballero, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|May 6, 2008
EORTC 22972-26991/MRC BR10 trial: fractionated stereotactic boost following conventional radiotherapy of high grade gliomas. Clinical and quality-assurance results of the stereotactic boost armBrigitta G Baumert, Michael Brada, Jacques Bernier, et al.
Pageof 16

Showing results (31-40 of 155) with videos related to

Sort By:
Pageof 16
BMC Medical Research Methodology|October 5, 2022
The case against censoring of progression-free survival in cancer clinical trials - A pandemic shutdown as an illustrationCorinne Jamoul, Laurence Collette, Elisabeth Coart, et al.
JAMA Network Open|May 17, 2021
Association of Increased Prostate-Specific Antigen Levels After Treatment and Mortality in Men With Locally Advanced vs Localized Prostate Cancer: A Secondary Analysis of 2 Randomized Clinical TrialsMartin T King, Ming-Hui Chen, Laurence Collette, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|August 9, 2011
Nomogram to predict ipsilateral breast relapse based on pathology review from the EORTC 22881-10882 boost versus no boost trialErik van Werkhoven, Guus Hart, Harm van Tinteren, et al.
The Lancet. Oncology|February 5, 2019
Towards an evidence-informed value scale for surgical and radiation oncology: a multi-stakeholder perspectiveYolande Lievens, Riccardo Audisio, Ian Banks, et al.
The Lancet. Oncology|April 4, 2019
ESMO-MCBS: setting the record straight - Authors' replyYolande Lievens, Riccardo Audisio, Ian Banks, et al.
Biometrical Journal. Biometrische Zeitschrift|September 17, 2020
A new measure of treatment effect in clinical trials involving competing risks based on generalized pairwise comparisonsEva Cantagallo, Mickaël De Backer, Michal Kicinski, et al.
Biometrical Journal. Biometrische Zeitschrift|February 22, 2021
Correcting the bias of the net benefit estimator due to right-censored observationsJulien Péron, Maryam Idlhaj, Delphine Maucort-Boulch, et al.
Acta Oncologica (Stockholm, Sweden)|June 24, 2008
Results of the phase II EORTC 22971 trial evaluating combined accelerated external radiation and chemotherapy with 5FU and cisplatin in patients with muscle invasive transitional cell carcinoma of the bladderPhilip M Poortmans, Pierre Richaud, Laurence Collette, et al.
Japanese Journal of Clinical Oncology|February 8, 2017
Collaboration between EORTC and JCOG-how to accelerate global clinical research partnershipKozo Kataoka, Kenichi Nakamura, Carmela Caballero, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|May 6, 2008
EORTC 22972-26991/MRC BR10 trial: fractionated stereotactic boost following conventional radiotherapy of high grade gliomas. Clinical and quality-assurance results of the stereotactic boost armBrigitta G Baumert, Michael Brada, Jacques Bernier, et al.
Pageof 16